Simplifying Sepsis-Induced Coagulopathy Scoring

Evidence

Sepsis-induced coagulopathy (SIC) is a scoring construct built from platelet count, prothrombin time-international normalized ratio, and part of the Sequential Organ Failure Assessment (SOFA). Two independent clinical studies examined different questions about that construct. A new retrospective analysis tested whether the SOFA component could be removed without losing the ability to identify progression toward overt disseminated intravascular coagulation (DIC). An earlier prospective study measured SIC and SOFA repeatedly to determine how their trajectories related to 28-day mortality.

The 2026 SIC-2 study analyzed 18,086 patients with sepsis in the MIMIC-IV critical-care database. The researchers compared the original SIC definition with a simplified, coagulation-centered version that excluded SOFA. They evaluated discrimination and calibration for overt DIC within five ICU days, 28-day mortality, and days free of ICU care or ventilation. This was a retrospective score-comparison study, not a test of a treatment or a prospective bedside intervention.

For overt DIC, original SIC and SIC-2 had similarly strong discrimination: the reported areas under the receiver operating characteristic curve were 0.850 and 0.854, respectively, with no statistically significant difference (p = 0.37). For 28-day mortality, the original score performed slightly better, with AUCs of 0.621 for SIC and 0.614 for SIC-2. That difference was statistically significant in the large dataset, but its absolute size was only 0.007. Both scores were significantly associated with ICU-free and ventilator-free days, with marginally stronger separation for original SIC. Under the study's non-inferiority interpretation, removing SOFA preserved prediction of the overt-DIC trajectory while giving up a small amount of general prognostic information.

The independent 2024 study provides a temporal view. It prospectively enrolled adults with sepsis arriving at one tertiary emergency department in Beijing and assessed SIC and SOFA on days 1, 2, and 4. After exclusions, 209 participants were analyzed; their median age was 83, 60.3% were male, and 78 of 209 died within 28 days. Pulmonary infection was the most common recorded site, present in 78.9% of participants.

The trajectories separated survivors from non-survivors. Among non-survivors, SIC and SOFA scores increased across the first four days. Among survivors, both rose temporarily on day 2, then fell by day 4 to below day-1 levels. SIC did not significantly separate the groups on day 1, but non-survivors had higher scores on days 2 and 4. Mortality discrimination likewise improved with later measurement: SIC AUC was 0.545 on day 1, 0.601 on day 2, and 0.749 on day 4. The change in SIC from day 1 to day 4 had an AUC of 0.758, while day-4 SOFA had an AUC of 0.763.

In an adjusted Cox model, meeting SIC criteria on day 4 was associated with 28-day mortality, with a hazard ratio of 3.736 and a 95% confidence interval of 2.025 to 6.891. Day-2 SIC was not independently associated with mortality in the corresponding model. This association does not establish that the score caused the outcome; it shows that persistent coagulation and organ-dysfunction abnormalities marked a higher-risk course in this cohort.

Analysis — Different scores for different questions

The cross-study signal is that a score's best design depends on the question it is being asked to answer. In the MIMIC-IV analysis, removing SOFA barely changed discrimination for overt DIC, the coagulation-specific endpoint, but modestly reduced mortality discrimination. That pattern is consistent with the authors' interpretation that SOFA adds information about downstream organ dysfunction rather than coagulation alone. The prospective study independently showed that SOFA and SIC moved together as illness evolved, and that later trajectories separated survivors from non-survivors more clearly than the admission SIC snapshot.

A reasonable analysis is therefore to separate phenotype from prognosis. SIC-2 may provide a conceptually cleaner research phenotype for early coagulation abnormality, while repeated SIC and SOFA measurements carry broader information about the course of critical illness. The evidence does not show that one score should replace another in clinical practice. The studies used different populations, designs, and endpoints, and they did not directly compare SIC-2 trajectories prospectively. Their convergence instead identifies a testable next step: external prospective work could examine whether a coagulation-only score preserves early DIC detection across settings while longitudinal organ-failure measures remain separately informative about outcomes.

Limitations

The SIC-2 evidence was available in the ingested pack only as a PubMed abstract. Full methods were therefore unavailable for auditing cohort construction, missing-data handling, calibration results, non-inferiority margins, subgroup performance, and the exact timing of score inputs. MIMIC-IV is a retrospective critical-care database, so the findings may reflect its documentation and case mix. High AUC for a database endpoint also does not by itself demonstrate prospective clinical usefulness.

The prospective study was small and single-center, and its cohort was unusually old, with a median age of 83. It excluded people with prior thrombocytopenia, coagulopathy, serious liver disease, hematopoietic malignancy, pregnancy, warfarin exposure, and those who died within 24 hours. Only 186 participants contributed day-4 analyses, reducing the later sample and introducing survivorship concerns. Infection sites were not mutually exclusive in the report.

Neither study tested whether score-guided management improved outcomes, and neither result establishes a treatment effect. SIC-2 also requires independent validation outside MIMIC-IV and direct comparison with original SIC over repeated time points. These findings refine how researchers may distinguish coagulation biology from overall sepsis severity; they do not support individual diagnostic or treatment decisions.